small molecule

VENCLEXTA

VENETOCLAX

Loss of exclusivitySeptember 2033latest FDA-listed patent expiry

CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand name	VENCLEXTA
Active ingredient	VENETOCLAX
Strength	50MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2016
Marketing status	RX

Listed patents

Patent	Expires	Type
9539251	September 2033	use U-2538
11413282	September 2033	use U-3412
11590128	September 2033	use U-3548
10993942	September 2033	use U-3114
11110087	September 2033	use U-3223
11369599	May 2032	product
8722657	January 2032	substance
10730873	November 2031	substance
8546399	June 2031	substance, product
9174982	May 2030	use U-2445

Regulatory exclusivity

Code	Expires
ODE-239	May 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from AbbVie Inc.